Current animal models of obsessive compulsive disorder: An update

Neuroscience

Volumn 211, Issue , 2012, Pages 83-106

  Albelda, N ^a   Joel, D ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Behavioral model; Genetic model; Mice; Obsessive compulsive disorder (OCD); Pharmacological model; Rat

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ARIPIPRAZOLE; CLOMIPRAMINE; CYCLOSERINE; DESIPRAMINE; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; ESTRADIOL; FLUOXETINE; GONADORELIN AGONIST; HALOPERIDOL; MEMANTINE; NOMIFENSINE; PRASTERONE SULFATE; QUINPIROLE; RILUZOLE; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE;

AROMATASE GENE; CONSTRUCT VALIDITY; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG SCREENING; EXPERIMENTAL TEST; FACE VALIDITY; GENE; GENETIC MODEL; HIGH FREQUENCY STIMULATION; HUMAN; LEARNING; MARBLE BURYING; NERVE STIMULATION; NESTING; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORBITAL CORTEX; PERSEVERATION; POLYDIPSIA; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RESPONSE TIME; REVIEW; SAPAP3 GENE; SEROTONINERGIC SYSTEM; SEX DIFFERENCE; SIGNAL ATTENUATION; SIGNAL TRANSDUCTION; SLITRK5 GENE; STEREOTYPY; SUBTHALAMIC NUCLEUS;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; OBSESSIVE-COMPULSIVE DISORDER; REPRODUCIBILITY OF RESULTS;

EID: 84860621526     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.08.070     Document Type: Review

References (256)

1. Abbruzzese M., Bellodi L., Ferri S., Scarone S. Frontal lobe dysfunction in schizophrenia and obsessive-compulsive disorder: a neuropsychological study. Brain Cogn 1995, 27:202-212.
2. Aboujaoude E., Barry J.J., Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009, 29:51-55.
3. Abramowitz J.S., Schwartz S.A., Moore K.M., Luenzmann K.R. Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. J Anxiety Disord 2003, 17:461-478.
4. Agrati D., Fernández-Guasti A., Zuluaga M.J., Uriarte N., Pereira M., Ferreira A. Compulsive-like behaviour according to the sex and the reproductive stage of female rats. Behav Brain Res 2005, 161:313-319.
5. Albelda N, Joel D (in press) Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci Biobehav Rev, in press.
6. Albelda N., Bar-On N., Joel D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology 2010, 210:13-24.
7. Altemus M., Glowa J.R., Galliven E., Leong Y.M., Murphy D.L. Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol Biochem Behav 1996, 53:123-131.
8. Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, American Psychiatric Press, Washington, DC. 4th ed.
9. Andersen S.L., Greene-Colozzi E.A., Sonntag K.C. A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals. Biol Psychiatry 2010, 68:741-747.
10. Andrade P., Fernández-Guasti A., Carrillo-Ruiz J.D., Ulloa R.E., Ramírez Y., Reyes R., Jiménez F. Effects of bilateral lesions in thalamic reticular nucleus and orbitofrontal cortex in a T-maze perseverative model produced by 8-OH-DPAT in rats. Behav Brain Res 2009, 203:108-112.
11. Aouizerate B., Cuny E., Martin-Guehl C., Guehl D., Amieva H., Benazzouz A., Fabrigoule C., Allard M., Rougier A., Bioulac B., Tignol J., Burbaud P. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg 2004, 101:682-686.
12. Aouizerate B., Martin-Guehl C., Cuny E., Guehl D., Amieva H., Benazzouz A., Fabrigoule C., Bioulac B., Tignol J., Burbaud P. Deep brain stimulation for OCD and major depression. Am J Psychiatry 2005, 162:2192.
13. Argyropoulos S.V., Sandford J.J., Nutt D.J. The psychobiology of anxiolytic drugs. Part 2: pharmacological treatments of anxiety. Pharmacol Ther 2000, 88:213-227.
14. Arnold P.D., Rosenberg D.R., Mundo E., Tharmalingam S., Kennedy J.L., Richter M.A. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004, 174:530-538.
15. Asbahr F.R., Garvey M.A., Snider L.A., Zanetta D.M., Elkis H., Swedo S.E. Obsessive-compulsive symptoms among patients with Sydenham chorea. Biol Psychiatry 2005, 57:1073-1076.
16. Atmaca M., Tezcan E., Kuloglu M., Ustundag B. Plasma nitrate values in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci 2005, 59:621-623.
17. Bari A., Dalley J.W., Robbins T.W. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 2008, 3:759-767.
18. Bari A., Theobald D.E., Caprioli D., Mar A.C., Aidoo-Micah A., Dalley J.W., Robbins T.W. Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats. Neuropsychopharmacology 2010, 35:1290-1301.
19. Bartz J.A., Hollander E. Is obsessive-compulsive disorder an anxiety disorder?. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:338-352.
20. Baumgarten H.G., Grozdanovic Z. Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998, 13-20.
21. Baxter L.R. Functional imaging of brain systems mediating obsessive-compulsive disorder. Neurobiology of mental illness 1999, 534-547. Oxford University Press, New-York. C.E. Nestler, W. Bunney (Eds.).
22. Baxter L.R., Phelps M.E., Mazziotta J.C., Guze B.H., Schwartz J.M., Selin C.E. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987, 44:211-218.
23. Baxter L.R., Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., Alazraki A., Selin C.E., Ferng H.K., Munford P., et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49:681-689.
24. Benkelfat C., Nordahl T.E., Semple W.E., King A.C., Murphy D.L., Cohen R.M. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. Arch Gen Psychiatry 1990, 47:840-848.
25. Berney A., Sookman D., Leyton M., Young S.N., Benkelfat C. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry 2006, 59:853-857.
26. Berridge K.C., Aldridge J.W., Houchard K.R., Zhuang X. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biol 2005, 3:4.
27. Berthier M.L., Kulisevsky J., Gironell A., Heras J.A. Obsessive-compulsive disorder associated with brain lesions: clinical phenomenology, cognitive function, and anatomic correlates. Neurology 1996, 47:353-361.
28. Bewernick B.H., Hurlemann R., Matusch A., Kayser S., Grubert C., Hadrysiewicz B., Axmacher N., Lemke M., Cooper-Mahkorn D., Cohen M.X., Brockmann H., Lenartz D., Sturm V., Schlaepfer T.E. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2010, 67:110-116.
29. Bigos K.L., Folan M.M., Jones M.R., Haas G.L., Kroboth F.J., Kroboth P.D. Dysregulation of neurosteroids in obsessive compulsive disorder. J Psychiatr Res 2009, 43:442-445.
30. Biojone C., Casarotto P.C., Resstel L.B., Zangrossi H., Guimares F.S., Moreira F.A. Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. J Psychopharmacol 2010, 25:801-807.
31. Bloch M.H., Landeros-Weisenberger A., Sen S., Dombrowski P., Kelmendi B., Coric V., Pittenger C., Leckman J.F. Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:850-858.
32. Boulougouris V., Dalley J.W., Robbins T.W. Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat. Behavioural Brain Research 2007, 179:219-228.
33. Boulougouris V., Glennon J.C., Robbins T.W. Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 2007, 33:2007-2019.
34. Braff D.L. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Behavioral neurobiology of schizophrenia and its treatment 2010, Vol. 4:349-371. Springer, Berlin Heidelberg. N.R. Swerdlow (Ed.).
35. Brandes M., Soares C.N., Cohen L.S. Postpartum onset obsessive-compulsive disorder: diagnosis and management. Arch Womens Ment Health 2004, 7:99-110.
36. Breiter H.C., Rauch S.L., Kwong K.K., Baker J.R., Weisskoff R.M., Kennedy D.N., Kendrick A.D., Davis T.L., Jiang A., Cohen M.S., Stern C.E., Belliveau J.W., Baer L., O'Sullivan R.L., Savage C.R., Jenike M.A., Rosen B.R. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 1996, 53:595-606.
37. Broekkamp C.L., Jenck F. The relationship between various animal models of anxiety, fear-related psychiatric symptoms and response to serotonergic drugs. Behavioural pharmacology of 5-HT 1989, 321-335. Erlbaum, Hillsdale. P. Bevan, R. Cools, T. Archer (Eds.).
38. Broekkamp C.L., Rijk H.W., Joly-Gelouin D., Lloyd K.L. Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 1986, 126:223-229.
39. Broocks A., Pigott T.A., Hill J.L., Canter S., Grady T.A., L'Heureux F., Murphy D.L. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res 1998, 79:11-20.
40. Bult A., Lynch C.B. Multiple selection responses in house mice bidirectionally selected for thermoregulatory nest-building behavior: crosses of replicate lines. Behav Genet 1996, 26:439-446.
41. Bult A., Lynch C.B. Nesting and fitness: lifetime reproductive success in house mice bidirectionally selected for thermoregulatory nest-building behavior. Behav Genet 1997, 27:231-240.
42. Bult A., Lynch C.B. Breaking through artificial selection limits of an adaptive behavior in mice and the consequences for correlated responses. Behav Genet 2000, 30:193-206.
43. Campbell K.M., de Lecea L., Severynse D.M., Caron M.G., McGrath M.J., Sparber S.B., Sun L.-Y., Burton F.H. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci 1999, 19:5044-5053.
44. Campbell K.M., McGrath M.J., Burton F.H. Behavioral effects of cocaine on a transgenic mouse model of cortical-limbic compulsion. Brain Res 1999, 833:216-224.
45. Campbell K.M., McGrath M.J., Burton F.H. Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists. Eur J Pharmacol 1999, 371:103-111.
46. Casas M., Alvarez E., Duro P., Garcia-Ribera C., Udina C., Velat A., Abella D., Rodriguez-Espinosa J., Salva P., Jané F. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986, 73:221-222.
47. Catapano F., Monteleone P., Maj M., Kemali D. Dexamethasone suppression test in patients with primary obsessive-compulsive disorder and in healthy controls. Neuropsychobiology 1990, 23:53-56.
48. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005, 30:1735-1740.
49. Chamberlain S.R., Blackwell A.D., Fineberg N.A., Robbins T.W., Sahakian B.J. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005, 29:399-419.
50. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., Heninger G.R. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 1988, 45:177-185.
51. Chou-Green J.M., Holscher T.D., Dallman M.F., Akana S.F. Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiol Behav 2003, 78:641-649.
52. Chudasama Y., Passetti F., Rhodes S.E.V., Lopian D., Desai A., Robbins T.W. Dissociable aspects of performance on the 5-choice serial reaction time task following lesions of the dorsal anterior cingulate, infralimbic and orbitofrontal cortex in the rat: differential effects on selectivity, impulsivity and compulsivity. Behav Brain Res 2003, 146:105-119.
53. Clark L., Blackwell A.D., Aron A.R., Turner D.C., Dowson J., Robbins T.W., Sahakian B.J. Association between response inhibition and working memory in adult ADHD: a link to right frontal cortex pathology?. Biol Psychiatry 2007, 61:1395-1401.
54. Clarke H.F., Walker S.C., Dalley J.W., Robbins T.W., Roberts A.C. Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb Cortex 2007, 17:18-27.
55. Cools R., Altamirano L., D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006, 44:1663-1673.
56. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., Saksa J., Wu Y.T., Gueorguieva R., Sanacora G., Malison R.T., Krystal J.H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005, 58:424-428.
57. Di Giovanni G., Di Matteo V., Pierucci M., Esposito E. Serotonin-dopamine interaction: electrophysiological evidence. Prog Brain Res 2008, 172:45-71.
58. Di Matteo V., De Blasi A., Di Giulio C., Esposito E. Role of 5-HT2C receptors in the control of central dopamine function. Trends Pharmacol Sci 2001, 22:229-232.
59. Dvorkin A., Silva C., McMurran T., Bisnaire L., Foster J., Szechtman H. Features of compulsive checking behavior mediated by nucleus accumbens and orbital frontal cortex. Eur J Neurosci 2010, 32:1552-1563.
60. Eddy K.T., Dutra L., Bradley R., Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004, 24:1011-1030.
61. Egashira N., Harada S., Okuno R., Matsushita M., Nishimura R., Mishima K., Iwasaki K., Orito K., Fujiwara M. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. Eur J Pharmacol 2007, 563:149-154.
62. Egashira N., Okuno R., Harada S., Matsushita M., Mishima K., Iwasaki K., Nishimura R., Oishi R., Fujiwara M. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 2008, 586:164-170.
63. Egashira N., Okuno R., Matsushita M., Abe M., Mishima K., Iwasaki K., Nishimura R., Oishi R., Fujiwara M. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. Eur J Pharmacol 2008, 592:103-108.
64. Eilam D., Szechtman H. Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: an ethological approach to the form of compulsive rituals. CNS Spectr 2005, 10:191-202.
65. Eriksson T. Antiandrogenic treatment for obsessive-compulsive disorder. Am J Psychiatry 2000, 157:483.
66. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2007, 31:1556-1571.
67. Fernández-Guasti A., Agrati D., Reyes R., Ferreira A. Ovarian steroids counteract serotonergic drugs actions in an animal model of obsessive-compulsive disorder. Psychoneuroendocrinology 2006, 31:924-934.
68. Fernandez-Guasti A., Ulloa R.E., Nicolini H. Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder. Psychopharmacology (Berl) 2003, 166:195-201.
69. Fisher C.R., Graves K.H., Parlow A.F., Simpson E.R. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci U S A 1998, 95:6965-6970.
70. Flaisher-Grinberg S., Albelda N., Gitter L., Weltman K., Arad M., Joel D. Ovarian hormones modulate "compulsive" lever-pressing in female rats. Horm Behav 2009, 55:356-365.
71. Flaisher-Grinberg S., Klavir O., Joel D. The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2008, 11:811-825.
72. Forrest A., Hewett A., Nicholson P. Controlled randomized group comparison of nomifensine and imipramine in depressive illness. Br J Clin Pharmacol 1977, 4(Suppl 2):215S-220S.
73. Frankel M., Cummings J.L., Robertson M.M., Trimble M.R., Hill M.A., Benson D.F. Obsessions and compulsions in Gilles de la Tourette's syndrome. Neurology 1986, 36:378-382.
74. Fumagalli F., Pasini M., Frasca A., Drago F., Racagni G., Riva M.A. Prenatal stress alters glutamatergic system responsiveness in adult rat prefrontal cortex. J Neurochem 2009, 109:1733-1744.
75. Garner J.P., Dufour B., Gregg L.E., Weisker S.M., Mench J.A. Social and husbandry factors affecting the prevalence and severity of barbering ([']whisker trimming') by laboratory mice. Appl Anim Behav Sci 2004, 89:263-282.
76. Gauggel S., Rieger M., Feghoff T.-A. Inhibition of ongoing responses in patients with Parkinson's disease. J Neurol Neurosurg, Psychiatry 2004, 75:539-544.
77. Geyer M.A., Markow A. Animal models of psychiatric disorders. Psychopharmacology: the fourth generation of progress 1995, 787-789. Raven Press, Ltd., New York, NY. F.E. Bloom, D.J. Kupfer (Eds.).
78. Goddard A.W., Shekhar A., Whiteman A.F., McDougle C.J. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today 2008, 13:325-332.
79. Goodman W.K., McDougle C.J., Price L.H., Barr L.C., Hills O.F., Caplik J.F., Charney D.S., Heninger G.R. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 1995, 38:138-149.
80. Grad L.R., Pelcovitz D., Olson M., Matthews M., Grad G.J. Obsessive-compulsive symptomatology in children with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1987, 26:69-73.
81. Grant P., Lougee L., Hirschtritt M., Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007, 17:761-767.
82. Gray J.A. The neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system 1982, Oxford University Press, New-York.
83. Greenberg B.D., Gabriels L.A., Malone D.A., Rezai A.R., Friehs G.M., Okun M.S., Shapira N.A., Foote K.D., Cosyns P.R., Kubu C.S., Malloy P.F., Salloway S.P., Giftakis J.E., Rise M.T., Machado A.G., Baker K.B., Stypulkowski P.H., Goodman W.K., Rasmussen S.A., Nuttin B.J. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 2010, 15:64-79.
84. Greenberg B.D., Malone D.A., Friehs G.M., Rezai A.R., Kubu C.S., Malloy P.F., Salloway S.P., Okun M.S., Goodman W.K., Rasmussen S.A. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006, 31:2384-2393.
85. Greene-Schloesser D.M., Van der Zee E.A., Sheppard D.K., Castillo M.R., Gregg K.A., Burrow T., Foltz H., Slater M., Bult-Ito A. Predictive validity of a non-induced mouse model of compulsive-like behavior. Behav Brain Res 2011, 221:55-62.
86. Greer J.M., Capecchi M.R. Hoxb8 is required for normal grooming behavior in mice. Neuron 2002, 33:23-34.
87. Greist J.H., Jefferson J.W. Obsessive-compulsive disorder. Focus 2007, 5:283-298.
88. Gross-Isseroff R., Cohen R., Sasson Y., Hillary V., Zohar J. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 2004, 50:200-205.
89. Güldenpfennig M., Wolmarans D.W., du Preez J.L., Stein D.J., Harvey B.H. Cortico-striatal oxidative status, dopamine turnover and relation with stereotypy in the deer mouse. Physiol Behav 2011, 103:404-411.
90. Gyertyán I. Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behav Pharmacol 1995, 6:24-31.
91. Habermann W. A review of controlled studies with nomifensine, performed outside the UK. Br J Clin Pharmacol 1977, 4(Suppl2):237S-241S.
92. Hedlund P.B., Sutcliffe J.G. The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder. Neurosci Lett 2007, 414:247-251.
93. Hill R.A., McInnes K.J., Gong E.C., Jones M.E., Simpson E.R., Boon W.C. Estrogen deficient male mice develop compulsive behavior. Biol Psychiatry 2007, 61:359-366.
94. Hirano K., Kimura R., Sugimoto Y., Yamada J., Uchida S., Kato Y., Hashimoto H., Yamada S. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 2005, 144:695-702.
95. Ho Pian K.L., Westenberg H.G.M., den Boer J.A., de Bruin W.I., van Rijk P.P. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls. Biol Psychiatry 1998, 44:367-370.
96. Hogg S., Dalvi A. Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists. Pharmacol Biochem Behav 2004, 77:69-75.
97. Hollander E., DeCaria C., Gully R., Nitescu A., Suckow R.F., Gorman J.M., Klein D.F., Liebowitz M.R. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 1991, 36:1-17.
98. Hozumi A., Hirata K., Tanaka H., Yamazaki K. Perseveration for novel stimuli in Parkinson's disease: an evaluation based on event-related potentials topography. Mov Disord 2000, 15:835-842.
99. Huddy V.C., Aron A.R., Harrison M., Barnes T.R.E., Robbins T.W., Joyce E.M. Impaired conscious and preserved unconscious inhibitory processing in recent onset schizophrenia. Psychol Med 2009, 39:907-916.
100. Huff W., Lenartz D., Schormann M., Lee S.-H., Kuhn J., Koulousakis A., Mai J., Daumann J., Maarouf M., Klosterkötter J., Sturm V. Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: outcomes after one year. Clin Neurol Neurosurg 2010, 112:137-143.
101. Hugo F., van Heerden B., Zungu-Dirwayi N., Stein D.J. Functional brain imaging in obsessive-compulsive disorder secondary to neurological lesions. Depress Anxiety 1999, 10:129-136.
102. Ichimaru Y., Egawa T., Sawa A. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 1995, 68:65-70.
103. Insel T.R., Mos J., Olivier B. Animal models of obsessive compulsive disorder: a review. Current insights in obsessive compulsive disorder 1994, 117-135. John Wiley and Sons, Chichester. E. Hollander, J. Zohar, D. Marazzitti, B. Olivier (Eds.).
104. Itami S., Uno H. Orbitofrontal cortex dysfunction in attention-deficit hyperactivity disorder revealed by reversal and extinction tasks. Neuroreport 2002, 13:2453-2457.
105. Jiménez F., Velasco F., Salín-Pascual R., Velasco M., Nicolini H., Velasco A.L., Castro G. Neuromodulation of the inferior thalamic peduncle for major depression and obsessive compulsive disorder. Acta Neurochir Suppl 2007, 97:393-398.
106. Jiménez-Ponce F., Velasco-Campos F., Castro-Farfán G., Nicolini H., Velasco A.L., Salín-Pascual R., Trejo D., Criales J.L. Preliminary study in patients with obsessive-compulsive disorder treated with electrical stimulation in the inferior thalamic peduncle. Neurosurgery 2009, 65:203-209. discussion 209.
107. Joel D. Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:374-388.
108. Joel D. The signal attenuation rat model of obsessive-compulsive disorder: a review. Psychopharmacology (Berl) 2006, 186:487-503.
109. Joel D., Ben-Amir E., Doljansky J., Flaisher S. "Compulsive" lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam. Behav Pharmacol 2004, 15:241-252.
110. Joel D., Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D1, but not D2, blockade: possible implications for the involvement of D1 receptors in obsessive-compulsive disorder. Neuropsychopharmacology 2003, 28:77-85.
111. Joel D., Doljansky J., Roz N., Rehavi M. Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 2005, 130:25-36.
112. Joel D., Doljansky J., Schiller D. "Compulsive" lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex. Eur J Neurosci 2005, 21:2252-2262.
113. Joel D., Klavir O. The effects of temporary inactivation of the orbital cortex in the signal attenuation rat model of obsessive compulsive disorder. Behav Neurosci 2006, 120:976-983.
114. Joel D., Stein D.J., Schreiber R. Animal models of obsessive-compulsive disorder: from bench to bedside via endophenotypes and biomarkers. Animal and translational models for CNS drug discovery, Vol. 1: Psychiatric disorders 2008, 133-164. Elsevier, Amsterdam. R.A. McArthur, F. Borsini (Eds.).
115. Karayiorgou M., Altemus M., Galke B.L., Goldman D., Murphy D.L., Ott J., Gogos J.A. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A 1997, 94:4572-4575.
116. Khanna S., John J.P., Reddy L.P. Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder. Psychoneuroendocrinology 2001, 26:209-223.
117. Klavir O., Flash S., Winter C., Joel D. High frequency stimulation and pharmacological inactivation of the subthalamic nucleus reduces "compulsive" lever-pressing in rats. Exp Neurol 2009, 215:101-109.
118. Klavir O., Winter C., Joel D. High but not low frequency stimulation of both the globus pallidus and the entopeduncular nucleus reduces "compulsive lever-pressing in rats. Behav Brain Res 2011, 216:84-93.
119. Korff S., Harvey B.H. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am 2006, 29:371-390.
120. Korff S., Stein D.J., Harvey B.H. Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:348-355.
121. Korff S., Stein D.J., Harvey B.H. Cortico-striatal cyclic AMP-phosphodiesterase-4 signalling and stereotypy in the deer mouse: attenuation after chronic fluoxetine treatment. Pharmacol Biochem Behav 2009, 92:514-520.
122. Krass M., Rünkorg K., Wegener G., Volke V. Nitric oxide is involved in the regulation of marble-burying behavior. Neurosci Lett 2010, 480:55-58.
123. Külz A.K., Meinzer S., Kopasz M., Voderholzer U. Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results. Neuropsychobiology 2007, 56:127-131.
124. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., McCabe J., Peterson J., Foa E.B. d-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007, 62:835-838.
125. Labad J., Menchón J.M., Alonso P., Segalàs C., Jiménez S., Vallejo J. Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry 2005, 66:428-435. quiz 546.
126. Lochner C., Hemmings S.M.J., Kinnear C.J., Moolman-Smook J.C., Corfield V.A., Knowles J.A., Niehaus D.J.H., Stein D.J. Gender in obsessive-compulsive disorder: clinical and genetic findings. Eur Neuropsychopharmacol 2004, 14:105-113.
127. Lochner C., Stein D.J. Heterogeneity of obsessive-compulsive disorder: a literature review. Harv Rev Psychiatry 2003, 11:113.
128. Londei T., Valentini A.M.V., Leone V.G. Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 1998, 94:249-254.
129. Lopes A.C., de Mathis M.E., Canteras M.M., Salvajoli J.V., Del Porto J.A., Miguel E.C. Update on neurosurgical treatment for obsessive compulsive disorder. Rev Bras Psiquiatr 2004, 26:62-66.
130. Maina G., Albert U., Bogetto F., Vaschetto P., Ravizza L. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999, 89:49-58.
131. Mallet L., Polosan M., Jaafari N., Baup N., Welter M.L., Fontaine D., du Montcel S.T., Yelnik J., Chéreau I., Arbus C., Raoul S., Aouizerate B., Damier P., Chabardès S., Czernecki V., Ardouin C., Krebs M.O., Bardinet E., Chaynes P., Burbaud P., Cornu P., Derost P., Bougerol T., Bataille B., Mattei V., Dormont D., Devaux B., Vérin M., Houeto J.L., Pollak P., Benabid A.L., Agid Y., Krack P., Millet B., Pelissolo A. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med 2008, 359:2121-2134.
132. Malloy P. Frontal lobe dysfunction in obsessive compulsive disorder. The frontal lobes revisited 1987, IRBN Press, New York. E. Perecman (Ed.).
133. Malone D.A., Dougherty D.D., Rezai A.R., Carpenter L.L., Friehs G.M., Eskandar E.N., Rauch S.L., Rasmussen S.A., Machado A.G., Kubu C.S., Tyrka A.R., Price L.H., Stypulkowski P.H., Giftakis J.E., Rise M.T., Malloy P.F., Salloway S.P., Greenberg B.D. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009, 65:267-275.
134. Man J., Hudson A.L., Ashton D., Nutt D.J. Animal models for obsessive-compulsive disorder. Curr Neuropharmacol 2004, 2:169-181.
135. Marek G.J. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development. International review of neurobiology 2007, 78:165-192.
136. Martin J.R., Bös M., Jenck F., Moreau J.-L., Mutel V., Sleight A.J., Wichmann J., Andrews J.S., Berendsen H.H.G., Broekkamp C.L.E., Ruigt G.S.F., Köhler C., van Delft A.M.L. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998, 286:913-924.
137. Masi G., Pfanner C., Millepiedi S., Berloffa S. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2010, 30:688-693. 610.1097/JCP.1090b1013e3181fab1097b1091.
138. Mataix-Cols D., Rosario-Campos M.C., Leckman J.F. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005, 162:228-238.
139. Mathews C.A., Kaur N., Stein M.B. Childhood trauma and obsessive-compulsive symptoms. Depress Anxiety 2008, 25:742-751.
140. Matthysse S. Animal models in psychiatric research. Prog Brain Res 1986, 65:259-270.
141. McCormick C.M., Smythe J.W., Sharma S., Meaney M.J. Sex-specific effects of prenatal stress on hypothalamic-pituitary-adrenal responses to stress and brain glucocorticoid receptor density in adult rats. Dev Brain Res 1995, 84:55-61.
142. McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994, 51:302-308.
143. McDougle C.J., Goodman W.K., Price L.H., Delgado P.L., Krystal J.H., Charney D.S., Heninger G.R. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990, 147:652-654.
144. McGrath M.J., Campbell K.M., Burton F.H. The role of cognitive and affective processing in a transgenic mouse model of cortical-limbic neuropotentiated compulsive behavior. Behav Neurosci 1999, 113:1249-1256.
145. McGrath M.J., Campbell K.M., Veldman M.B., Burton F.H. Anxiety in a transgenic mouse model of cortical-limbic neuro-potentiated compulsive behavior. Behav Pharmacol 1999, 10:435-443.
146. McKinney W.T. Models of mental disorders: a new comparative psychiatry 1969, Plenum Medical Book Co., New York, NY.
147. McKinney W.T., Bunney W.E. Animal model of depression. I. Review of evidence: implications for research. Arch Gen Psychiatry 1969, 21:240-248.
148. Menzies L., Chamberlain S.R., Laird A.R., Thelen S.M., Sahakian B.J., Bullmore E.T. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 2008, 32:525-549.
149. Minkeviciene R., Banerjee P., Tanila H. Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology 2008, 54:1079-1085.
150. Moritz S., Hottenrott B., Randjbar S., Klinge R., Von Eckstaedt F.V., Lincoln T.M., Jelinek L. Perseveration and not strategic deficits underlie delayed alternation impairment in obsessive-compulsive disorder (OCD). Psychiatry Res 2009, 170:66-69.
151. Mundt A., Klein J., Joel D., Heinz A., Djodari-Irani A., Harnack D., Kupsch A., Orawa H., Juckel G., Morgenstern R., Winter C. High-frequency stimulation of the nucleus accumbens core and shell reduces quinpirole-induced compulsive checking in rats. Eur J Neurosci 2009, 29:2401-2412.
152. Murphy D.L., Li Q., Engel S., Wichems C., Andrews A., Lesch K.P., Uhl G. Genetic perspectives on the serotonin transporter. Brain Res Bull 2001, 56:487-494.
153. Murphy D.L., Zohar J., Benkelfat C., Pato M.T., Pigott T.A., Insel T.R. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder. Br J Psychiatry Suppl 1989, 15-24.
154. Muscatello M.R.A., Bruno A., Pandolfo G., Micò U., Scimeca G., Romeo V.M., Santoro V., Settineri S., Spina E., Zoccali R.A. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2011, 31:174-179. 110.1097/JCP.1090b1013e31820e31823db31826.
155. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 2003, 41:268-287.
156. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991, 38:63-67.
157. Nonogaki K., Strack A.M., Dallman M.F., Tecott L.H. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998, 4:1152-1156.
158. Nordstrom E.J., Burton F.H. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry 2002, 7:617-625. 524.
159. Otto M.W. Normal and abnormal information processing. A neuropsychological perspective on obsessive compulsive disorder. Psychiatr Clin North Am 1992, 15:825-848.
160. Ozaki N., Goldman D., Kaye W.H., Plotnicov K., Greenberg B.D., Lappalainen J., Rudnick G., Murphy D.L. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 2003, 8:933-936.
161. Peciña S., Cagniard B., Berridge K.C., Aldridge J.W., Zhuang X. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 2003, 23:9395-9402.
162. Pigott T.A., Hill J.L., Grady T.A., L'Heureux F., Bernstein S., Rubenstein C.S., Murphy D.L. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry 1993, 33:3-14.
163. Pigott T.A., L'Heureux F., Bernstein S.E., Hill J.L., Murphy D. A controlled comparative therapeutic trial of clomipramine and m-chlorophenylpiperazin (mCPP) in patients with obsessive-compulsive disorder 1992.
164. Pitman R.K. A cybernetic model of obsessive-compulsive psychopathology. Compr Psychiatry 1987, 28:334-343.
165. Pitman R.K. Animal models of compulsive behavior. Biol Psychiatry 1989, 26:189-198.
166. Pitman R. Historical considerations. The psychobiology of obsessive-compulsive disorder 1991, 1-12. Springer Publishing Company, New York. J. Zohar, T. Insel, S. Rasmussen (Eds.).
167. Pitman R.K., Green R.C., Jenike M.A., Mesulam M.M. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatry 1987, 144:1166-1171.
168. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3:69-81.
169. Platt B., Beyer C.E., Schechter L.E., Rosenzweig-Lipson S. Schedule-induced polydipsia: a rat model of obsessive-compulsive disorder. Current protocols in neuroscience 2001, John Wiley & Sons, Inc., New-York, NY.
170. Powell S.B., Newman H.A., Pendergast J.F., Lewis M.H. A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors. Physiol Behav 1999, 66:355-363.
171. Presti M.F., Lewis M.H. Striatal opioid peptide content in an animal model of spontaneous stereotypic behavior. Behav Brain Res 2005, 157:363-368.
172. Presti M.F., Mikes H.M., Lewis M.H. Selective blockade of spontaneous motor stereotypy via intrastriatal pharmacological manipulation. Pharmacol Biochem Behav 2003, 74:833-839.
173. Ralph-Williams R.J., Paulus M.P., Zhuang X., Hen R., Geyer M.A. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry 2003, 53:352-359.
174. Rasmussen S.A., Eisen J.L. The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin North Am 1992, 15:743-758.
175. Rauch S.L., Dougherty D.D., Malone D., Rezai A., Friehs G., Fischman A.J., Alpert N.M., Haber S.N., Stypulkowski P.H., Rise M.T., Rasmussen S.A., Greenberg B.D. A functional neuroimaging investigation of deep brain stimulation in patients with obsessive-compulsive disorder. J Neurosurg 2006, 104:558-565.
176. Rauch S.L., Jenike M.A., Alpert N.M., Baer L., Breiter H.C., Savage C.R., Fischman A.J. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994, 51:62-70.
177. Reed G.F. Obsessional personality disorder and remembering. Br J Psychiatry 1977, 130:177-183.
178. Ricciardi J.N., Hurley J. Development of animal models of obsessive-compulsive disorders. Obsessive-compulsive disorders: theory and management 1990, 189-199. Year Book Medical Publishers, Inc, Chicago. M.A. Jenike, L. Baer, W.E. Minichiello (Eds.).
179. Richardson H.N., Zorrilla E.P., Mandyam C.D., Rivier C.L. Exposure to repetitive versus varied stress during prenatal development generates two distinct anxiogenic and neuroendocrine profiles in adulthood. Endocrinology 2006, 147:2506-2517.
180. Richman C., Dember W., Kim P. Spontaneous alternation behavior in animals: a review. Curr Psychol 1986, 5:358-391.
181. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 2002, 163:362-380.
182. Robinson E.S.J., Eagle D.M., Mar A.C., Bari A., Banerjee G., Jiang X., Dalley J.W., Robbins T.W. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 2008, 33:1028-1037.
183. Rocha B.A., Goulding E.H., O'Dell L.E., Mead A.N., Coufal N.G., Parsons L.H., Tecott L.H. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci 2002, 22:10039-10045.
184. Rogers R.D., Baunez C., Everitt B.J., Robbins T.W. Lesions of the medial and lateral striatum in the rat produce differential deficits in attentional performance. Behav Neurosci 2001, 115:799-811.
185. Rosenzweig-Lipson S., Sabb A., Stack G., Mitchell P., Lucki I., Malberg J.E., Grauer S., Brennan J., Cryan J.F., Sukoff Rizzo S.J., Dunlop J., Barrett J.E., Marquis K.L. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology 2007, 192:159-170.
186. Rotge J.-Y., Langbour N., Guehl D., Bioulac B., Jaafari N., Allard M., Aouizerate B., Burbaud P. Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation meta-analysis. Neuropsychopharmacology 2009, 35:686-691.
187. Sarkar R., Klein J., Krüger S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology 2008, 197:687-688.
188. Sasson Y., Zohar J. New developments in obsessive-compulsive disorder research: implications for clinical management. Int Clin Psychopharmacol 1996, 11(Suppl 5):3-12.
189. Sasson Y., Zohar J., Chopra M., Lustig M., Iancu I., Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997, 58(Suppl 12):7-10.
190. Saxena S., Brody A.L., Maidment K.M., Dunkin J.J., Colgan M., Alborzian S., Phelps M.E., Baxter L.R. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999, 21:683-693.
191. Saxena S., Brody A.L., Schwartz J.M., Baxter L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998, 26-37.
192. Saxena S., Wang D., Bystritsky A., Baxter L.R. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996, 57:303-306.
193. Schilman E.A., Klavir O., Winter C., Sohr R., Joel D. The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system. Neuropsychopharmacology 2010, 35:1026-1039.
194. Schneider T., Popik P. Attenuation of estrous cycle-dependent marble burying in female rats by acute treatment with progesterone and antidepressants. Psychoneuroendocrinology 2007, 32:651-659.
195. Seibell P.J., Demarest J., Rhoads D.E. 5-HT1A receptor activity disrupts spontaneous alternation behavior in rats. Pharmacol Biochem Behav 2003, 74:559-564.
196. Seu E., Jentsch D.J. Effect of acute and repeated treatment with desipramine or methylphenidate on serial reversal learning in rats. Neuropharmacology 2009, 57:665-672.
197. Seu E., Lang A., Rivera R.J., Jentsch J.D. Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys. Psychopharmacology 2009, 202:505-519.
198. Shmelkov S.V., Hormigo A., Jing D., Proenca C.C., Bath K.G., Milde T., Shmelkov E., Kushner J.S., Baljevic M., Dincheva I., Murphy A.J., Valenzuela D.M., Gale N.W., Yancopoulos G.D., Ninan I., Lee F.S., Rafii S. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med 2010, 16:598-602. 1p following 602.
199. Starck G., Ljungberg M., Nilsson M., Jönsson L., Lundberg S., Ivarsson T., Ribbelin S., Ekholm S., Carlsson A., Forssell-Aronsson E., Carlsson M.L. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm 2008, 115:1051-1062.
200. Stein D.J. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000, 47:296-304.
201. Stein D.J., Dodman N.H., Borchelt P., Hollander E. Behavioral disorders in veterinary practice: relevance to psychiatry. Compr Psychiatry 1994, 35:275-285.
202. Stein D.J., Van Heerden B., Wessels C.J., Van Kradenburg J., Warwick J., Wasserman H.J. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry 1999, 23:1079-1099.
203. Stern L., Zohar J., Cohen R., Sasson Y. Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur Neuropsychopharmacol 1998, 8:325-328.
204. Sturm V., Lenartz D., Koulousakis A., Treuer H., Herholz K., Klein J.C., Klosterkötter J. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat 2003, 26:293-299.
205. Suárez J., Llorente R., Romero-Zerbo S.Y., Mateos B., Bermúdez-Silva F.J., de Fonseca F.R., Viveros M.P. Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. Hippocampus 2009, 19:623-632.
206. Swedo S.E., Pietrini P., Leonard H.L., Schapiro M.B., Rettew D.C., Goldberger E.L., Rapoport S.I., Rapoport J.L., Grady C.L. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry 1992, 49:690-694.
207. Szechtman H., Eckert M.J., Tse W.S., Boersma J.T., Bonura C.A., McClelland J.Z., Culver K.E., Eilam D. Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci 2001, 2:4.
208. Szechtman H., Eilam D. Psychiatric models. The behavior of the laboratory rat: a handbook with tests 2005, 462-474. Oxford University Press, Inc, London. I.Q. Whishaw, B. Kolb (Eds.).
209. Szechtman H., Sulis W., Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 1998, 112:1475-1485.
210. Szechtman H., Woody E. Obsessive-compulsive disorder as a disturbance of security motivation. Psychol Rev 2004, 111:111-127.
211. Takeuchi H., Yatsugi S., Yamaguchi T. Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model. Jpn J Pharmacol 2002, 90:197-200.
212. Tass P.A., Klosterkötter J., Schneider F., Lenartz D., Koulousakis A., Sturm V. Obsessive-compulsive disorder: development of demand-controlled deep brain stimulation with methods from stochastic phase resetting. Neuropsychopharmacology 2003, 28:S27-S34.
213. Tecott L.H., Logue S.F., Wehner J.M., Kauer J.A. Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice. Proc Natl Acad Sci USA 1998, 95:15026-15031.
214. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., Julius D. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995, 374:542-546.
215. Thomas A., Burant A., Bui N., Graham D., Yuva-Paylor L.A., Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 2009, 204:361-373.
216. Treit D. The inhibitory effect of diazepam on defensive burying: anxiolytic vs. analgesic effects. Pharmacol Biochem Behav 1985, 22:47-52.
217. Treit D., Pinel J.P.J., Fibiger H.C. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 1981, 15:619-626.
218. Tsaltas E., Kontis D., Chrysikakou S., Giannou H., Biba A., Pallidi S., Christodoulou A., Maillis A., Rabavilas A. Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology. Biol Psychiatry 2005, 57:1176-1185.
219. Uday G., Pravinkumar B., Manish W., Sudhir U. LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur J Pharmacol 2007, 563:155-159.
220. Uguz F., Gezginc K., Zeytinci I.E., Karatayli S., Askin R., Guler O., Sahin F.K., Emul H.M., Ozbulut O., Gecici O. Course of obsessive-compulsive disorder during early postpartum period: a prospective analysis of 16 cases. Compr Psychiatry 2007, 48:558-561.
221. Ulloa R.-E., Nicolini H., Fernández-Guasti A. Sex differences on spontaneous alternation in prepubertal rats: implications for an animal model of obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2004, 28:687-692.
222. Umathe S., Bhutada P., Dixit P., Shende V. Increased marble-burying behavior in ethanol-withdrawal state: modulation by gonadotropin-releasing hormone agonist. Eur J Pharmacol 2008, 587:175-180.
223. Umathe S.N., Bhutada P.S., Jain N.S., Mundhada Y.R., Borkar S.S., Dhumal B. Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice. Nitric Oxide 2009, 21:140-147.
224. Umathe S.N., Vaghasiya J.M., Jain N.S., Dixit P.V. Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1161-1166.
225. Van Den Buuse M., Simpson E.R., Jones M.E.E. Prepulse inhibition of acoustic startle in aromatase knock-out mice: effects of age and gender. Genes Brain Behav 2003, 2:93-102.
226. van Kuyck K., Brak K., Das J., Rizopoulos D., Nuttin B. Comparative study of the effects of electrical stimulation in the nucleus accumbens, the mediodorsal thalamic nucleus and the bed nucleus of the stria terminalis in rats with schedule-induced polydipsia. Brain Res 2008, 1201:93-99.
227. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuro-Psychopharmacol Biol Psychiatry 2003, 27:85-102.
228. Vickers S.P., Clifton P.G., Dourish C.T., Tecott L.H. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 1999, 143:309-314.
229. Viveros M.P., Llorente R., López-Gallardo M., Suarez J., Bermúdez-Silva F., De la Fuente M., Rodriguez de Fonseca F., Garcia-Segura L.M. Sex-dependent alterations in response to maternal deprivation in rats. Psychoneuroendocrinology 2009, 34(Suppl 1):S217-S226.
230. Volke V., Soosaar A., Koks S., Bourin M., Mannisto P.T., Vasar E. 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl) 1997, 131:399-405.
231. Waford R.N., Lewine R. Is perseveration uniquely characteristic of schizophrenia?. Schizophr Res 2010, 118:128-133.
232. Walf A.A., Frye C.A. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology 2006, 31:1097-1111.
233. Waltz J.A., Gold J.M. Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophr Res 2007, 93:296-303.
234. Wang L., Simpson H.B., Dulawa S.C. Assessing the validity of current mouse genetic models of obsessive-compulsive disorder. Behav Pharmacol 2009, 20:119-133.
235. Welch J.M., Lu J., Rodriguiz R.M., Trotta N.C., Peca J., Ding J.D., Feliciano C., Chen M., Adams J.P., Luo J., Dudek S.M., Weinberg R.J., Calakos N., Wetsel W.C., Feng G. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007, 448:894-900.
236. Westenberg H.G., Fineberg N.A., Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 2007, 12:14-27.
237. Wilber A.A., Southwood C.J., Sokoloff G., Steinmetz J.E., Wellman C.L. Neonatal maternal separation alters adult eyeblink conditioning and glucocorticoid receptor expression in the interpositus nucleus of the cerebellum. Dev Neurobiol 2007, 67:1751-1764.
238. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., Cannistraro P., Jenike M.A., Rauch S.L. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008, 165:335-341. quiz 409.
239. Willner P. The validity of animal models of depression. Psychopharmacology (Berl) 1984, 83:1-16.
240. Willner P. Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 1986, 10:677-690.
241. Willner P. Behavioural models in psychopharmacology. Behavioural models in psychopharmacology: theoretical, industrial and clinical perspectives 1999, Cambridge University Press, Cambridge. P. Willner (Ed.).
242. Winslow J.T., Insel T.R. Neuroethological models of obsessive-compulsive disorder. The psychobiology of obsessive-compulsive disorder 1991, 208-226. Springer Publishing Company, New York. J. Zohar, T. Insel, S. Rasmussen (Eds.).
243. Winter C., Flash S., Klavir O., Klein J., Sohr R., Joel D. The role of the subthalamic nucleus in "compulsive" behavior in rats. Eur J Neurosci 2008, 27:1902-1911.
244. Winter C., Mundt A., Jalali R., Joel D., Harnack D., Morgenstern R., Juckel G., Kupsch A. High frequency stimulation and temporary inactivation of the subthalamic nucleus reduce quinpirole-induced compulsive checking behavior in rats. Exp Neurol 2008, 210:217-228.
245. Witkin J.M. Animal models of obsessive-compulsive disorder. Curr Protoc Neurosci 2008, Chapter 9:Unit 9.30.
246. Wood M.D., Wren P.B. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. Progress in brain research 2008, 172:213-230.
247. Woods A., Smith C., Szewczak M., Dunn R.W., Cornfeldt M., Corbett R. Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl) 1993, 112:195-198.
248. Worthington J.J., Kinrys G., Wygant L.E., Pollack M.H. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005, 20:9-11.
249. Yadin E., Friedman E., Bridger W.H. Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder?. Pharmacol Biochem Behav 1991, 40:311-315.
250. Zadicario P., Ronen S., Eilam D. Modulation of quinpirole-induced compulsive-like behavior in rats by environmental changes: implications for OCD rituals and for exploration and navigation. BMC Neurosci 2007, 8:23.
251. Zhang J., Huang X.Y., Ye M.L., Luo C.X., Wu H.Y., Hu Y., Zhou Q.G., Wu D.L., Zhu L.J., Zhu D.Y. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J Neurosci 2010, 30:2433-2441.
252. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A 2001, 98:1982-1987.
253. Zohar A.H. The epidemiology of obsessive-compulsive disorder in children and adolescents. Child Adolesc Psychiatr Clin N Am 1999, 8:445-460.
254. Zohar J., Insel T.R. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987, 22:667-687.
255. Zohar J., Zohar-Kadouch R.C., Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 1992, 43:210-218.
256. Zuena A.R., Mairesse J., Casolini P., Cinque C., Alemà G.S., Morley-Fletcher S., Chiodi V., Spagnoli L.G., Gradini R., Catalani A., Nicoletti F., Maccari S. Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats. PLoS One 2008, 3:e2170.